We are developing molecular tests designed to improve the diagnostic accuracy of cytology samples, thereby helping to increase the utility of these minimally invasive procedures as an alternative to surgical biopsy. Our Goal: Enable Doctors to Make More Informed Treatment Decisions Our Focus: Molecular Cytology
Company Growth (employees)
South San Francisco, US
Size (employees)
216 (est)+13%
Veracyte was founded in 2008 and is headquartered in South San Francisco, US

Key People at Veracyte

Bonnie Anderson

Bonnie Anderson

Co-Founder & CEO
Shelly D. Guyer

Shelly D. Guyer

Richard Lanman

Richard Lanman

Chief Medical Officer
Giulia C. Kennedy

Giulia C. Kennedy

Chief Scientific Officer
Chris Hall

Chris Hall

Chief Commercial Officer
Robert Monroe

Robert Monroe

VP, Laboratory Operations & Medical Director

Veracyte Office Locations

Veracyte has offices in South San Francisco and Austin
South San Francisco, US (HQ)
300 6000 Shoreline Ct
Austin, US
100 12357 Riata Trace Pkwy

Veracyte Metrics

Veracyte Financial Metrics

Revenue (2016)

$65.1 m

Revenue growth (2015-16), %


Net income (2016)

($31.4 m)

Market capitalization (28-Apr-2017)

$286.7 m

Closing share price (28-Apr-2017)


Cash (31-Dec-2016)

$59.2 m
Veracyte's current market capitalization is $286.7 m.
Veracyte's revenue was reported to be $65.1 m in FY, 2016 which is a 31% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$21.9 m$38.2 m$49.5 m$65.1 m

Revenue growth, %


Cost of goods sold

$16.6 m

Gross profit

$9.3 m$21.6 m$28 m

Gross profit Margin, %


Operating expense total

$45.1 m$67.2 m$83 m


($23.2 m)($29 m)($33.5 m)

EBIT margin, %


Interest expense

$439 k

Net Income

($25.6 m)($29.4 m)($33.7 m)($31.4 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$71.2 m$35 m$39.1 m$59.2 m

Accounts Receivable

$8.8 m


$1.5 m$1.2 m$1.5 m$2.1 m

Current Assets

$76.4 m$43.3 m$47.9 m$73.6 m


$3 m$4.2 m$10.3 m$11.5 m


$1.1 m$1.1 m$1.1 m

Total Assets

$79.6 m$64.8 m$75.3 m$101 m

Accounts Payable

$5.3 m$7.4 m$5.1 m$2.4 m

Current Liabilities

$15.4 m$17.1 m$14.7 m$11.5 m

Additional Paid-in Capital

$142.1 m$156.4 m$200 m$239.6 m

Retained Earnings

($85.6 m)($115 m)($148.7 m)($180.1 m)

Total Equity

$56.4 m$41.4 m$51.3 m$59.6 m

Financial Leverage

1.4 x1.6 x1.5 x1.7 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($25.6 m)($29.4 m)($33.7 m)($31.4 m)

Depreciation and Amortization

$999 k$1.2 m$2.3 m$3.5 m

Accounts Receivable

($683 k)($2 m)($558 k)($5.3 m)


$304 k

Accounts Payable

$3.3 m$1.9 m($3.5 m)($1.4 m)

Cash From Operating Activities

($19.2 m)($27.6 m)($27 m)($28 m)

Purchases of PP&E

($1.3 m)($2 m)($6.2 m)($4.2 m)

Cash From Investing Activities

($1.3 m)($9 m)($6.7 m)($4.2 m)

Cash From Financing Activities

$77.7 m$436 k$37.7 m$52.3 m

Veracyte Market Value History

Veracyte Online Presence

Veracyte Company Life

You may also be interested in